Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Leukemia 8Leukemia, Myeloid, Chronic-Phase 7Burkitt Lymphoma 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma 3Philadelphia Chromosome 2Pancreatic Neoplasms 2Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Glioma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostate Cancer Recurrent 1Primary Myelofibrosis 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm, Residual 1

Interventions

venetoclax 1ruxolitinib 1pevonedistat 1Imatinib Mesylate 1Dasatinib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypereosinophilic Syndrome × Dasatinib × 1 year × Clear all
NCT00255346 2025-12-30

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡